Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants

Simple item page
dc.contributor.authorCooper, Curtis L
dc.contributor.authorRead, Daniel
dc.contributor.authorVachon, Marie-Louise
dc.contributor.authorConway, Brian
dc.contributor.authorWong, Alexander
dc.contributor.authorRamji, Alnoor
dc.contributor.authorBorgia, Sergio
dc.contributor.authorTam, Ed
dc.contributor.authorBarrett, Lisa
dc.contributor.authorSmyth, Dan
dc.contributor.authorFeld, Jordan J
dc.contributor.authorLee, Sam
dc.date.accessioned2020-09-06T00:09:16Z
dc.date.available2020-09-06T00:09:16Z
dc.date.issued2020-09-03
dc.date.updated2020-09-06T00:09:16Z
dc.description.abstractAbstract Background There are multiple obstacles encountered by immigrants attempting to engage hepatitis C virus (HCV) care and treatment. We evaluated the diversity and treatment outcomes of HCV-infected immigrants evaluated for Direct Acting Antiviral (DAA) therapy in Canada. Methods The Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort contains demographic information and DAA treatment information prospectively collected at 10 Canadian sites. Information on country of origin and race are collected. Characteristics and outcomes (sustained virological response; SVR) were compared by immigration status and race. Results Between January 2016 and May 2018, 725 HCV-infected patients assessed for DAA therapy were enrolled in CANUHC (mean age: 52.66 ± 12.68 years); 65.66% male; 82.08% White, 5.28% Indigenous, 4.64% South East Asian, 4.64% East Indian, 3.36% Black). 18.48% were born outside of Canada. Mean age was similar [immigrants: 54.36 ± 13.95 years), Canadian-born: 52.27 ± 12.35 years); (p = 0.085)]. The overall baseline fibrosis score (in kPa measured by transient elastography) was similar among Canadian and foreign-born patients. Fibrosis score was not predicted by race or genotype. The proportion initiating DAA therapy was similar by immigrant status (56.72% vs 49.92%). SVR rates by intent-to-treat analysis were similar (immigrants-89.47%, Canadian-born-92.52%; p = 0.575). Conclusion A diverse immigrant population is engaging care in Canada, initiating HCV antiviral therapy in an equitable fashion and achieving SVR proportions similar to Canada-born patients. Our Canadian experience may be of value in informing HCV elimination efforts in economically developed regions.
dc.identifier.citationBMC Public Health. 2020 Sep 03;20(1):1345
dc.identifier.doihttps://doi.org/10.1186/s12889-020-09464-0
dc.identifier.urihttp://hdl.handle.net/1880/112497
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleHepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12889_2020_Article_9464.pdf
Size:
652.68 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications